Preventive Cardiovascular

LDL Levels Among Statin-Tolerant Adults

Primary and Secondary Prevention

Primary Cardiovascular Disease Prevention: Statin-Tolerant Adults

2016 – 2020, N = 366

Patients taking statins for primary cardiovascular disease prevention experienced reductions in low-density lipoprotein (LDL) cholesterol levels. Patients were seen at baseline, defined as their first visit, and had at least 2 follow-up visits within the past 2 years. The time between visits varied from patient to patient.

LDL = low-density lipoprotein

Source: EPIC

Lab values were somewhat limited due to COVID-19. Fluctuations in 2020 volumes are a result of significant changes to the number of patients treated, which can be directly attributed to the COVID-19 pandemic.

Secondary Cardiovascular Disease Prevention: Statin-Tolerant Adults

2016 – 2020, N = 330

Patients taking statins for secondary cardiovascular disease prevention experienced reductions in low-density lipoprotein (LDL) cholesterol levels. Patients were seen at baseline, defined as their first visit, and had at least 2 follow-up visits within the past 2 years. The time between visits varied from patient to patient.

LDL = low-density lipoprotein

Source: EPIC

Lab values were somewhat limited due to COVID-19. Fluctuations in 2020 volumes are a result of significant changes to the number of patients treated, which can be directly attributed to the COVID-19 pandemic.